Whole-Body Nanoparticle Aerosol Inhalation Exposures

Distinct profiles of oxylipid mediators in liver, lung, and placenta after maternal nano-TiO2 nanoparticle inhalation exposure

“…Particle characteristics have previously been determined, including primary particle size (21 nm), specic surface area (48.08 m 2 g −1 ), and zeta potential (−56.6 mV). 23,24 Animal model Female Sprague-Dawley (SD) rats were purchased pregnant from Hilltop Laboratories (Scottdale, PA) and housed in an American Association for Accreditation of Laboratory Animal Care (AAALAC) approved facility at West Virginia University (WVU). All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of West Virginia University (WVU) and approved by the Animal Care and Use Committee of WVU.…”

“…Particle characteristics have previously been determined, including primary particle size (21 nm), specific surface area (48.08 m 2 g −1 ), and zeta potential (−56.6 mV). 23,24…”

“…Environmental Science: Advances lung deposition (dose) with nano-TiO 2 aerosols, the equation D = FVCT was used 27 where F is the deposition fraction (10%), V is the minute ventilation (208.3 cc), C is mass concentration (mg m −3 ), and T equals the exposure duration (minutes). 23 The exposure paradigm (…”

“…[24][25][26] To estimate lung deposition (dose) with nano-TiO 2 aerosols, the equation D = FVCT was used 27 where F is the deposition fraction (10%), V is the minute ventilation (208.3 cc), C is mass concentration (mg m −3 ), and T equals the exposure duration (minutes). 23 The exposure paradigm (12 mg m −3 , 6 hours exposure, 6 days) produced a calculated cumulative lung deposition of 525 ± 16 mg with the last exposure occurring 24 hours prior to GD19. The calculations represent total lung deposition and do not account for lung clearance (MPPD Soware v 2.11, Arlington, VA).…”

Development and Characterization of a 96‐Well Exposure System for Safety Assessment of Nanomaterials

“…[34] These findings are largely based on in vivo studies. [35,36] At present, there are no validated systems for aerosol application of drugs or nanomaterials in a high-throughput format and for the rapid determination of effect thresholds. Such systems would be of great help in the field of occupational hazard potential analysis and in the risk assessment of new materials in the micro-and nanoscale regime, such as cellulose nanocrystals (CNC) for example.…”